NEW YORK --(BUSINESS WIRE)--Sep. 3, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the Company will participate in the following upcoming virtual investor conferences in September: Citi 15 th Annual BioPharma Virtual Conference 2020 on Wednesday, September 9 and Thursday, September 10,

NEW YORK --(BUSINESS WIRE)--Sep. 2, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on September 1, 2020 , the Company granted non-statutory stock options to purchase an aggregate of 34,000 shares of the Company’s common stock to two newly hired, non-executive employees.

NEW YORK --(BUSINESS WIRE)--Sep. 1, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the positive Phase 3 results from its GATHER1 clinical trial with Zimura ® (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to